2Whitehouse M. A policy framework for commissioning cancer services[J]. BMJ,1995,310(6992):1425-1426. 被引量：1
3Fleissig A, Jenkins V, Catt S, et al. Multidisciplinary teams in cancer care: are they effective in the UK? [J]. Lancet Oncol,2006,7(11):935-943. 被引量：1
4Saini KS, Taylor C, Ramirez A J, et al. Role of the multi- disciplinary team in breast cancer management: results from a large international survey involving 39 countries [J]. Ann Oncol,2012,23(4):853-859. 被引量：1
5Chinai N, Binteliffe F, Armstrong EM, et al. Does every patient need to be discussed at a muhidiseiplinary team meeting?[J]. Clin Radiol,2013,68(8):780-784. 被引量：1
6Kesson EM, Allardiee GM, George WD, et al. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women[J]. BMJ,2012,344:e2718. 被引量：1
7Morris E, Haward RA, Gilthorpe MS, et al. The impact ofthe Calman-Hine report on the processes and outcomes of care for Yorkshire's breast cancer patients[J]. Ann Oncol, 2007,19(2):284-291. 被引量：1
8Newman EA, Guest AB, Helvie MA, et al. Changes in sur- gical management resulting from case review at a breast cancer multidisciplinary tumor board[J]. Cancer,2006,107 (10):2346-2351. 被引量：1
10Staradub VL, Messenger KA, Hao N, et al. Changes in breast cancer therapy because of pathology second opi- nions[J]. Ann Surg Oncol,2002,9(10):982-987. 被引量：1
二级参考文献26
1Kocjan G, Bourgain C, Fassina A, et al. The role of breast FNAC in diagnosis and clinical management: a survey of current practice[J]. Cytopathology, 2008,19(5):271-278. 被引量：1
2Liebens F, Carly B, Cusumano P, et al. Breast cancer seeding associated with core needle biopsies: A systematic review[J]. Maturitas, 2009,62(2): 113-123. 被引量：1
3Fitzal F, Sporn E P, Draxler W, et al. Preoperative core needle biopsy does not increase local recurrence rate in breast cancer patients[J]. Breast Cancer Res Treat, 2006,97(1):9-15. 被引量：1
4Park SM, Lee DW, Jin SY, et al. Fine-needle aspiration cytology as the first pathological diagnostic modality in breast lesions: A comparison with core needle biopsy[J]. Basic Applied Pathology, 2010,3(1):1-6. 被引量：1
5Tamaki K, Sasano H, Ishida T, et al. Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER,PgR and HER2 status of breast cancer patients [ J ]. Cancer Sci,2010,101 (9):2074- 2079. 被引量：1
6Hunt K, Robb G, Strom E, et al. Breast Cancer[M]. 2nd ed. New York: Springer Science, 2008:168-169. 被引量：1
7Mueller-Holzner E, Frede T, Daniaux M, et al. Ultrasound-guided core needle biopsy of the breast: does frozen section give an accurate diagnosis? [J]. Breast Cancer Res Treat, 2007,106(3): 399-406. 被引量：1
8Uy G B, Laudico A V, Carnate J M, Jr., et al. Breast cancer hormone receptor assay results of core needle biopsy and modified radical mastectomy specimens from the same patients [J]. Clin Breast Cancer, 2010,10(2): 154-159. 被引量：1
9Arnedos M, Nerurkar A, Osin P, et al. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC)[J]. Ann Oncol, 2009,20(12): 1948-1952. 被引量：1
10Youk J H, Kim E-K, Kim M J, et al. Analysis of false-negative results after US-guided 14-gauge core needle breast biopsy [ J ]. Eur Radiol, 2010,20(4):782-789. 被引量：1
4Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis [J]. J Nati Cancer Inst,2005,97(3): 188-194. 被引量：1
5NCCN Clinical Practice Guidelines in Ontology (NCCNGuide- lines). Breast Cancer Version.2015 [EB/OL~. [2015-02-10]. http://www.nccn.org/professionals/physician_gls/f_guidelines. asp#breast. 被引量：1
6Goldhirsch A, Winer EP, Coates AS, et al.Personalizingthe treat- ment of women with early breast cancer: highlights of the St Gal- len International Expert Consensus on the Primary Therapy of E'arly Breast Cancer 2013 [J]. Ann Oneol,2013,24(9): 2206-2223. 被引量：1
7Valachis A,Mauri D, Polyzos NP, et al. Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis [J].Breast, 2011,20(6):485-490. 被引量：1
8Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant and ad- juvant trastuzumab in patients with HER2-positive locally ad-vanced breast cancer (NOAH): follow-up of a randomized con- trolled superiority trial with aparallel HER2-negative cohort [J]. Lancet Oncol,2014,15(6):640-647. 被引量：1
9Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31 [J]. J Clin Oncol,2011,29(25):3366-3373. 被引量：1
10Buzdar AU, Suman VJ, Meric-Bemstam F, et al. Fluorouracil, epirubiein, and eyelophosphamide (FEC-75) followed by pacli- taxel plus trastuzumab versus paclitaxel plus trastuzumab fol- lowed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a ran- domised, controlled,phase 3 trial [J]. Lancet Oneol,2013,14(13): 1317-1325. 被引量：1
